NEW YORK, June 9 (GenomeWeb News) - Epigenomics will collaborate with Stanford University in colorectal cancer research, the Frankfurt, Germany-based company said yesterday.
Under the agreement, Epigenomics and the Molecular Imaging Program at Stanford University will work with molecular imaging technologies and DNA methylation markers to determine the potential complementary benefits in early colon cancer diagnosis.
Traditional scans have a sensitivity of about 85 percent and a specificity of 71 percent in the initial diagnosis while the DNA methylation marker from Epigenomics has a sensitivity "between 50 and 65 percent" and a specificity of 95 percent, according to Cathy Lofton-Day in a statement for Epigenomics.
The study will combine both methods to increase sensitivity and specificity of colorectal cancer detection. Up to 120 patients will be enrolled in the study over a period of several months in a two-arm design. Up to 60 patients with confirmed colorectal cancer will be in one arm and up to 60 with other malignancies will be in the second arm.
The study is co-funded by Roche Diagnostics and Epigenomics.